<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Patents</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Phrontline Biopharma  details new B7-H3/EGFR bispecific ADCs</title>
      <description>
        <![CDATA[Phrontline Biopharma (Hangzhou) Co. Ltd. has prepared and tested bispecific antibody-drug conjugates (bsADCs) comprising a bispecific antibody targeting B7 homolog 3 (B7-H3; CD276) and EGFR (HER1; erbB1) linked to a cytotoxic drug. They are described as potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731089</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731089-phrontline-biopharma-details-new-b7-h3-egfr-bispecific-adcs</link>
    </item>
    <item>
      <title>Shanghai Allink Biotherapeutics patents anti-EGFR/MET bispecific ADCs</title>
      <description>
        <![CDATA[Shanghai Allink Biotherapeutics Co. Ltd. has discovered new bispecific antibody-drug conjugates comprising a bispecific monoclonal antibody linked to a cytotoxic drug potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731088</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731088-shanghai-allink-biotherapeutics-patents-anti-egfr-met-bispecific-adcs</link>
    </item>
    <item>
      <title>Dewpoint Therapeutics discovers new β-catenin modulators</title>
      <description>
        <![CDATA[Dewpoint Therapeutics Inc. has patented new β-catenin (CTNNB1) condensate modulators potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731087</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731087-dewpoint-therapeutics-discovers-new-catenin-modulators</link>
    </item>
    <item>
      <title>Aeovian Pharmaceuticals synthesizes new CD38 inhibitors</title>
      <description>
        <![CDATA[Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731086</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731086-aeovian-pharmaceuticals-synthesizes-new-cd38-inhibitors</link>
    </item>
    <item>
      <title>Foghorn Therapeutics discloses new EP300 degradation inducers</title>
      <description>
        <![CDATA[Foghorn Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a histone acetyltransferase p300 (EP300)-targeting moiety. As such, they are described as EP300 degradation inducers potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731085</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731085-foghorn-therapeutics-discloses-new-ep300-degradation-inducers</link>
    </item>
    <item>
      <title>Zhongshan Institute for Drug Discovery synthesizes YAP1/TEAD interaction inhibitors</title>
      <description>
        <![CDATA[Zhongshan Institute for Drug Discovery has divulged new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of cancer, neurodegeneration, malaria, AIDS, gout, diabetes, renal failure and cardiovascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731027</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731027-zhongshan-institute-for-drug-discovery-synthesizes-yap1-tead-interaction-inhibitors</link>
    </item>
    <item>
      <title>Architect Therapeutics reports new CDK2 inhibitors</title>
      <description>
        <![CDATA[Architect Therapeutics Inc. has identified new spiro heterocyclic cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer, myeloproliferative, autoimmune disease, inflammatory disorder, viral infections and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731026</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731026-architect-therapeutics-reports-new-cdk2-inhibitors</link>
    </item>
    <item>
      <title>TRPM4 antagonists disclosed in Universitätsklinikum Hamburg-Eppendorf patent</title>
      <description>
        <![CDATA[Universitätsklinikum Hamburg-Eppendorf has synthesized new transient receptor potential cation channel subfamily M member 4 (TRPM4) antagonists potentially useful for the treatment of neurodegeneration, multiple sclerosis and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731025</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731025-trpm4-antagonists-disclosed-in-universitatsklinikum-hamburg-eppendorf-patent</link>
    </item>
    <item>
      <title>Guardian Biosciences identifies new compounds for TBI</title>
      <description>
        <![CDATA[Guardian Biosciences LLC has discovered new D-β-hydroxybutyrate compounds potentially useful for the treatment of traumatic brain injury (TBI).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731024</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731024-guardian-biosciences-identifies-new-compounds-for-tbi</link>
    </item>
    <item>
      <title>Tango Therapeutics patents new HBS1L degradation inducers</title>
      <description>
        <![CDATA[Tango Therapeutics Inc. has disclosed new HBS1-like protein (HBS1L; HBS1) degradation inducers potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731023</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731023-tango-therapeutics-patents-new-hbs1l-degradation-inducers</link>
    </item>
    <item>
      <title>Yantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors</title>
      <description>
        <![CDATA[Yantai Rongchang Pharmaceutical Co. Ltd. has synthesized new GTPase KRAS mutant inhibitors potentially useful for the treatment of pancreatic cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731009</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731009-yantai-rongchang-pharmaceutical-reports-new-kras-mutant-inhibitors</link>
    </item>
    <item>
      <title>Antimicrobial compounds revealed in University of Hong Kong patent</title>
      <description>
        <![CDATA[The University of Hong Kong has patented new transcription antitermination protein NusB/N-utilization substance E (NusE) interaction inhibitors reported to be useful for the treatment of gram-positive or gram-negative bacterial infections and fungal infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731008</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731008-antimicrobial-compounds-revealed-in-university-of-hong-kong-patent</link>
    </item>
    <item>
      <title>Boyuan Pharmaceutical prepares new HSV inhibitors</title>
      <description>
        <![CDATA[Boyuan Pharmaceutical (Suzhou) Co. Ltd. has disclosed new herpes simplex virus (HSV) inhibitors potentially useful for the treatment of HSV infection and dementia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731007</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731007-boyuan-pharmaceutical-prepares-new-hsv-inhibitors</link>
    </item>
    <item>
      <title>Shanghai Jeyou Pharmaceutical patents LGALS3 inhibitors</title>
      <description>
        <![CDATA[Work at Shanghai Jeyou Pharmaceutical Co. Ltd. has led to the identification of new thioether-substituted galactopyranoside derivatives acting as galectin-3 (LGALS3) inhibitors. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731006</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731006-shanghai-jeyou-pharmaceutical-patents-lgals3-inhibitors</link>
    </item>
    <item>
      <title>Hefei Shengpu Pharmaceutical synthesizes new GTPase KRAS mutant inhibitors</title>
      <description>
        <![CDATA[Hefei Shengpu Pharmaceutical Technology Co. Ltd. has divulged new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731005</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731005-hefei-shengpu-pharmaceutical-synthesizes-new-gtpase-kras-mutant-inhibitors</link>
    </item>
    <item>
      <title>Shanghai Ailux Biotechnology synthesizes FGFR2-targeting ADCs</title>
      <description>
        <![CDATA[Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730963</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730963-shanghai-ailux-biotechnology-synthesizes-fgfr2-targeting-adcs</link>
    </item>
    <item>
      <title>Hangzhou Bio Sincerity Pharma-Tech identifies new exportin-1 receptor antagonists</title>
      <description>
        <![CDATA[Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730962</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730962-hangzhou-bio-sincerity-pharma-tech-identifies-new-exportin-1-receptor-antagonists</link>
    </item>
    <item>
      <title>University of California discloses new PRKACA-targeting PROTACs</title>
      <description>
        <![CDATA[The University of California has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to cAMP-dependent protein kinase catalytic subunit α (PRKACA) targeting moiety through a linker.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730961</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730961-university-of-california-discloses-new-prkaca-targeting-protacs</link>
    </item>
    <item>
      <title>Treeline Biosciences patents new RAS inhibitors</title>
      <description>
        <![CDATA[Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730960</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730960-treeline-biosciences-patents-new-ras-inhibitors</link>
    </item>
    <item>
      <title>Impact Therapeutics discovers new Wee1 inhibitors</title>
      <description>
        <![CDATA[Impact Therapeutics (Shanghai) Inc. has prepared and tested Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730959</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730959-impact-therapeutics-discovers-new-wee1-inhibitors</link>
    </item>
    <item>
      <title>Infensa Bioscience identifies new ASIC blockers</title>
      <description>
        <![CDATA[Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730945</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730945-infensa-bioscience-identifies-new-asic-blockers</link>
    </item>
    <item>
      <title>KRAS inhibitors disclosed in Sunrise Oncology patent</title>
      <description>
        <![CDATA[Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730944</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730944-kras-inhibitors-disclosed-in-sunrise-oncology-patent</link>
    </item>
    <item>
      <title>Ascletis Pharma divulges new GIPR and GLP-1R agonists</title>
      <description>
        <![CDATA[Ascletis Pharma (China) Co. Ltd. has reported new gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes, obesity, Alzheimer’s disease, osteoporosis, psoriasis, sleep apnea, inflammatory bowel and cardiovascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730943</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730943-ascletis-pharma-divulges-new-gipr-and-glp-1r-agonists</link>
    </item>
    <item>
      <title>Insmed reports new cathepsin C inhibitors</title>
      <description>
        <![CDATA[Insmed Inc. has identified new cathepsin C (dipeptidyl peptidase I; DPP1) inhibitors potentially useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730942</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730942-insmed-reports-new-cathepsin-c-inhibitors</link>
    </item>
    <item>
      <title>HK Inno.N patents new MAP4K1 inhibitors</title>
      <description>
        <![CDATA[HK Inno.N Corp. has disclosed new 5-cyclopropylpicolinamide derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730941</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730941-hk-innon-patents-new-map4k1-inhibitors</link>
    </item>
    <item>
      <title>Rongchang Pharmaceutical describes new Menin/KMT2A interaction inhibitors</title>
      <description>
        <![CDATA[Rongchang Pharmaceutical (Zibo) Co. Ltd. has patented new Menin (MEN1)/KMT2A (MLL) interaction inhibitors designed for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730918</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730918-rongchang-pharmaceutical-describes-new-menin-kmt2a-interaction-inhibitors</link>
    </item>
    <item>
      <title>Apelin receptor agonists disclosed in Zhuhai United Laboratories patent</title>
      <description>
        <![CDATA[Work at Zhuhai United Laboratories Co. Ltd. has led to the identification of new apelin receptor (APLNR) agonists reported to be useful for the treatment of diabetes, heart failure, muscle atrophy, chronic kidney disease, pulmonary hypertension, amyotrophic lateral sclerosis, atherosclerosis and Alzheimer’s disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730917</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730917-apelin-receptor-agonists-disclosed-in-zhuhai-united-laboratories-patent</link>
    </item>
    <item>
      <title>Nankai University and Tianjin Accendatech identify new compounds for liver cancer</title>
      <description>
        <![CDATA[A joint Nankai University and Tianjin Accendatech Technology Co. Ltd. patent describes new isoalantolactone derivatives reported to be useful for the treatment of liver cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730916</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730916-nankai-university-and-tianjin-accendatech-identify-new-compounds-for-liver-cancer</link>
    </item>
    <item>
      <title>Korea Research Institute of Chemical Technology reports new JAK1 inhibitors</title>
      <description>
        <![CDATA[A team at the Korea Research Institute of Chemical Technology has synthesized tetrahydroisoquinoline- or isoindoline-substituted [1,2,4]triazolo[1,5-<em>a</em>]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730915</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730915-korea-research-institute-of-chemical-technology-reports-new-jak1-inhibitors</link>
    </item>
    <item>
      <title>Solve Therapeutics patents new 5T4-targeting ADCs</title>
      <description>
        <![CDATA[Solve Therapeutics Inc. has prepared and tested new antibody-drug conjugates (ADCs) comprising a monoclonal antibody targeting trophoblast glycoprotein (TPBG; 5T4) covalently linked to cytotoxic drug and reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730914</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730914-solve-therapeutics-patents-new-5t4-targeting-adcs</link>
    </item>
  </channel>
</rss>
